Zydus receives final approval from the USFDA for Arsenic Trioxide Injection

Deepthi | Myequity news | Date : 14-11-2018 14:40:00 IST

Zydus Cadila has received the final approval from the USFDA to market Arsenic Trioxide Injection, 10 mg/ 10 ml (1 mg/ml) single-dose vial (US RLD —TRISENOX). It will be manufactured at Alidac Pharmaceuticals Ltd., the company's wholly-owned subsidiary located at SEZ, Ahmedabad. Arsenic Trioxide is used to treat a type of leukemia (acute promyelocytic leukemia-APL) when other types of treatment (e.g., chemotherapy) have not worked well or no longer work.

About Zydus Cadila:

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research—based pharmaceutical company by 2020


More from Myequity